GlaxoSmithKline (GSK) has announced that it has entered into a partnership with Russian pharmaceutical company, JSC Binnopharm in order to locally manufacture GSK vaccines in the country.
According to the agreement, GSK will provide the technological knowhow and supply vaccines while Binnopharm will be responsible for secondary manufacturing processes including filling and packaging of the vaccines.
Some of the GSK vaccines to be manufactured under Binnopharm trademark include the cervical cancer, rotavirus and pneumococcal vaccines with the Russian company also responsible for acquiring approval of their facilities in accordance with international current Good Manufacturing Practice (cGMP) standards.
Announcing the partnership, GSK's Emerging Markets & Asia Pacific's president Abbas Hussain said "This agreement is an example of the flexible approach we are taking to make innovative vaccines more available in emerging markets through local partnerships. GSK has one of the broadest and fastest growing vaccines businesses in the world. This alliance with Binnopharm should ensure that more of these innovative vaccines are made available in Russia to benefit public health."